Acurasset Therapeutics

Acurasset Therapeutics appears to be a private, early-stage biotechnology company spun out of Alexander Ploss's lab at Princeton University and focused on curative therapies for hepatitis B virus infection. Publicly available information indicates the company has been developing a novel small-molecule approach intended to inhibit host factors required for HBV replication. The company was highlighted in 2021 in connection with the BioNJ BioPartnering Conference, where Alexander Ploss, identified as president of Acurasset Therapeutics, presented the company. Compared with more visible biotech companies, Acurasset has a very limited public footprint, and detailed pipeline, financing, management, and operating data are not readily disclosed. Based on the available evidence, it fits as a preclinical infectious-disease biotech rather than a broad platform or services company.